Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

For decades, Americans struggling with pain had two options to find relief: over-the-counter medication such as ibuprofen, which often provided limited reprieve, or prescription opioids, and the ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.

"This action and the agency’s designations to expedite the drug’s development and review underscore FDA’s commitment to approving safe and effective alternatives to opioids for pain management.” ...

Evidence suggests that Journavx doesn't pose a risk of addiction as opioid medications do, making it a potentially safer alternative for pain management. "A new therapeutic class of non-opioid ...

Vertex's Chronic Pain Ambitions Hit Roadblock with LSR Data So much of Journavx's potential lies in chronic pain management. In December, Vertex revealed Phase 2 data evaluating Journavx in ...

The intriguing phenomenon of pain suppression was observed by Henry Beecher among soldiers during WWII. Pain, often deemed an unpleasant sensation, is actually a vital protective mechanism created by ...